S

SELLAS Life Sciences Group
D

SLS

1.26000
USD
-0.06
(-4.55%)
مغلق
حجم التداول
48,440
الربح لكل سهم
-0
العائد الربحي
-
P/E
-2
حجم السوق
99,013,294
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALT
    -0.19000
    (-2.87%)
    6.42000 USD
    A
    ARWR
    -1.040
    (-4.97%)
    19.900 USD
    I
    IMRN
    0.00000
    (0.00%)
    2.03000 USD
    P
    PAVM
    0.03250
    (4.22%)
    0.80250 USD
    T
    TNXP
    -0.53000
    (-5.48%)
    9.15000 USD
    المزيد
الأخبار
المقالات

العنوان: SELLAS Life Sciences Group

القطاع: Healthcare
الصناعة: Biotechnology
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.